Bioxytran Secures $1.6 million SPA to Extinguish Note & Fund Clinical Development
January 22, 2025 09:00 ET
|
BIOXYTRAN, INC.
- Repurchasing all convertible note overhang, and - Funding pre-clinical and clinical trials - Management forfeiting $460,000 in accrued payroll BOSTON, MASSACHUSETTS, Jan. 22, 2025 (GLOBE...